According to a new report by GBI on the global biopharm market, we can expect it to grow from $138 B in 2011 to more than $320 B by 2020 upping biopharmaceutical's percentage of market from its current 15.6%.
PharmTech Talk » Biopharma Industry Set to See New Technologies and New Therapies.
The report says more companies will incorporate disposables into their manufacturing to become more efficient and will use more microbial systems too. I'd like to see the data supporting the latter and what products that are expected to be made using microbial systems -- instead of say CHO cells.
Biosimilars are expected to boom (surprise, surprise). GBI is projecting biosimilar sales in the US to reach $9B by 2020. India, China and Korea are also expected to have very active biosimilar programs. India alone has more than 20 active biosimilar companies now with 55 products on the market -- including products like Enbrel and Rituxan that are still on patent in many Western countries. The South Korean government is heavily backing the biosimilars industry and has a goal of taking 22% global market share by 2020.
Posted by Bruce Lehr Oct 3rd 2012.
Comments